Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer - Trial NCT06363006
Access comprehensive clinical trial information for NCT06363006 through Pure Global AI's free database. This Phase 1 trial is sponsored by Peking Union Medical College Hospital and is currently Recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Peking Union Medical College Hospital
Timeline & Enrollment
Phase 1
Mar 11, 2024
Jan 01, 2027
Primary Outcome
ORR Full single-arm, open, multicenter prospective clinical study,Progression-free Survival (PFS)
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of cardonilizumab
 injection combined with TKI in second-line treatment of advanced hepatocellular carcinoma.
 The main questions it aims to answer are:
 
 - Objective response rate (ORR) for evaluation
 
 - Disease Control Rate (DCR); Duration of relief (DoR); Progression free survival (PFS);
 Total survival time (OS); Safetyใ
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06363006
Non-Device Trial